Aurobindo Pharma Ltd

Aurobindo Pharma Ltd

₹ 1,160 1.83%
05 Jun - close price
About

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

Key Points

Leading Pharmaceutical Company
The company is India’s 2nd-largest listed pharma company based on revenue & the largest generics company in the US. It is ranked among the top 10 generic companies in 8 European countries. [1]

  • Market Cap 67,940 Cr.
  • Current Price 1,160
  • High / Low 1,593 / 994
  • Stock P/E 19.5
  • Book Value 557
  • Dividend Yield 0.39 %
  • ROCE 14.3 %
  • ROE 11.2 %
  • Face Value 1.00

Pros

Cons

  • The company has delivered a poor sales growth of 6.55% over past five years.
  • Company has a low return on equity of 10.2% over last 3 years.
  • Company might be capitalizing the interest cost
  • Dividend payout has been low at 10.4% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
5,809 6,236 5,739 6,407 6,473 6,851 7,219 7,352 7,580 7,567 7,796 7,979 8,382
4,839 5,303 4,950 5,453 5,477 5,702 5,846 5,753 5,920 5,949 6,230 6,401 6,622
Operating Profit 970 933 790 954 996 1,149 1,373 1,599 1,660 1,618 1,566 1,578 1,760
OPM % 17% 15% 14% 15% 15% 17% 19% 22% 22% 21% 20% 20% 21%
-114 41 57 93 135 47 188 163 14 221 136 159 135
Interest 9 15 25 45 56 57 68 76 89 111 113 118 115
Depreciation 254 280 298 321 346 327 418 423 354 404 382 419 444
Profit before tax 594 679 523 680 730 812 1,076 1,262 1,230 1,324 1,207 1,200 1,335
Tax % 3% 23% 22% 28% 31% 30% 30% 26% 26% 31% 32% 30% 32%
576 520 410 491 506 570 752 940 907 918 817 846 903
EPS in Rs 9.84 8.88 6.99 8.38 8.64 9.74 12.92 15.98 15.51 15.69 13.95 14.44 15.42
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
8,089 12,103 13,772 14,910 16,463 19,564 23,099 24,775 23,455 24,855 29,002 31,724
5,951 9,524 10,579 11,469 12,691 15,612 18,249 19,497 19,060 21,148 23,176 25,173
Operating Profit 2,137 2,579 3,193 3,441 3,772 3,952 4,849 5,278 4,396 3,707 5,826 6,551
OPM % 26% 21% 23% 23% 23% 20% 21% 21% 19% 15% 20% 21%
18 81 200 115 105 70 166 3,195 152 291 366 622
Interest 310 160 257 67 78 263 305 74 49 140 290 457
Depreciation 313 333 392 428 558 668 967 1,055 1,127 1,245 1,522 1,649
Profit before tax 1,533 2,168 2,744 3,061 3,241 3,091 3,743 7,344 3,373 2,612 4,380 5,066
Tax % 24% 28% 26% 25% 25% 24% 24% 27% 22% 26% 28% 31%
1,169 1,571 2,024 2,301 2,423 2,364 2,844 5,334 2,647 1,928 3,169 3,484
EPS in Rs 20.12 26.98 34.61 39.29 41.36 40.36 48.56 91.05 45.20 32.90 54.15 59.49
Dividend Payout % 7% 8% 7% 6% 6% 6% 6% 4% 20% 23% 8% 0%
Compounded Sales Growth
10 Years: 10%
5 Years: 7%
3 Years: 11%
TTM: 9%
Compounded Profit Growth
10 Years: 8%
5 Years: 4%
3 Years: 8%
TTM: 7%
Stock Price CAGR
10 Years: 6%
5 Years: 9%
3 Years: 30%
1 Year: -8%
Return on Equity
10 Years: 15%
5 Years: 12%
3 Years: 10%
Last Year: 11%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 29 29 59 59 59 59 59 59 59 59 59 58
Reserves 3,721 5,127 7,229 9,313 11,622 13,832 16,766 21,871 24,517 26,781 29,784 32,595
3,769 4,451 5,041 3,364 4,770 6,967 5,826 5,339 2,851 5,286 6,648 8,263
1,970 3,303 3,568 3,464 4,492 5,414 6,113 6,147 6,211 7,379 8,227 8,869
Total Liabilities 9,490 12,910 15,896 16,200 20,942 26,271 28,765 33,416 33,638 39,505 44,717 49,785
2,722 3,706 4,180 4,834 6,521 8,475 9,396 9,374 10,532 11,024 14,493 16,428
CWIP 310 420 848 1,458 1,583 1,668 1,986 3,062 3,747 5,390 3,869 3,266
Investments 20 20 123 246 312 360 555 591 997 543 372 252
6,439 8,765 10,745 9,662 12,527 15,768 16,827 20,390 18,362 22,549 25,983 29,839
Total Assets 9,490 12,910 15,896 16,200 20,942 26,271 28,765 33,416 33,638 39,505 44,717 49,785

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
646 1,237 1,420 3,279 1,955 1,651 4,381 3,329 5,016 2,387 2,435 3,925
-819 -1,017 -1,446 -1,787 -1,927 -2,904 -1,563 597 -3,211 -3,971 -4,242 -1,876
118 93 365 -1,915 864 1,919 -1,947 -1,365 -2,969 1,814 800 120
Net Cash Flow -55 313 340 -424 892 666 871 2,561 -1,164 230 -1,007 2,169

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 119 107 122 68 68 64 68 52 62 66 61 66
Inventory Days 240 239 240 246 317 304 289 333 272 275 284 295
Days Payable 137 136 146 122 128 107 97 103 97 125 129 117
Cash Conversion Cycle 222 210 217 191 257 260 260 282 237 216 216 244
Working Capital Days 162 126 141 122 139 148 120 124 120 119 120 123
ROCE % 27% 27% 27% 25% 23% 18% 19% 18% 13% 9% 14% 14%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
51.83% 51.84% 51.84% 51.84% 51.84% 51.84% 51.84% 51.84% 51.80% 51.82% 51.82% 51.82%
20.71% 21.41% 22.31% 23.03% 24.12% 22.45% 20.72% 18.01% 16.73% 16.59% 16.29% 15.33%
17.30% 16.56% 14.90% 15.09% 15.73% 18.29% 20.60% 23.28% 24.77% 25.14% 25.21% 26.23%
10.15% 10.20% 10.96% 10.06% 8.31% 7.43% 6.85% 6.87% 6.69% 6.45% 6.67% 6.61%
No. of Shareholders 3,59,6843,58,4593,69,8283,43,6172,93,2142,59,6382,41,9442,44,5752,38,6222,48,4882,57,9622,69,323

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls